# Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

> **NCT04045795** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 56 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** isatuximab SAR650984 IV
- **DRUG:** pomalidomide
- **DRUG:** dexamethasone
- **DRUG:** isatuximab SAR650984 SC
- **DEVICE:** Investigational injector device

## Key facts

- **NCT ID:** NCT04045795
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-06
- **Primary completion:** 2024-03-27
- **Final completion:** 2024-03-27
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045795, "Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04045795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*